Single-cell sequencing of neonatal uterus reveals an Misr2+ endometrial progenitor indispensable for fertility

Hatice Duygu Saatcioglu1,2, Motohiro Kano1,2, Heiko Horn1,2,3, Lihua Zhang1,2, Wesley Samore4, Nicholas Nagykery1,2, Marie-Charlotte Meinsohn1,2, Minsuk Hyun5, Rana Suliman1,2, Joy Poulo1,2,3, Jennifer Hsu6, Caitlin Sacha6, Dan Wang7, Guangping Gao7, Kasper Lage1,2,3, Esther Oliva4, Mary E Morris Sabatini8, Patricia K Donahoe1,2, David Pépin1,2*

1Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Boston, United States; 2Department of Surgery, Harvard Medical School, Boston, United States; 3Stanley Center, Broad Institute of MIT and Harvard, Cambridge, United States; 4Department of Pathology, Massachusetts General Hospital, Boston, United States; 5Department of Neurobiology, Harvard Medical School, Boston, United States; 6Department of Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, United States; 7Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, United States; 8Department of Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, United States

Abstract
The Mullerian ducts are the anlagen of the female reproductive tract, which regress in the male fetus in response to MIS. This process is driven by subluminal mesenchymal cells expressing Misr2, which trigger the regression of the adjacent Mullerian ductal epithelium. In females, these Misr2+ cells are retained, yet their contribution to the development of the uterus remains unknown. Here, we report that subluminal Misr2+ cells persist postnatally in the uterus of rodents, but recede by week 37 of gestation in humans. Using single-cell RNA sequencing, we demonstrate that ectopic postnatal MIS administration inhibits these cells and prevents the formation of endometrial stroma in rodents, suggesting a progenitor function. Exposure to MIS during the first six days of life, by inhibiting specification of the stroma, dysregulates paracrine signals necessary for uterine development, eventually resulting in apoptosis of the Misr2+ cells, uterine hypoplasia, and complete infertility in the adult female.

DOI: https://doi.org/10.7554/eLife.46349.001

Introduction
In mammals, both sexes initially develop Mullerian ducts, consisting of a single layer of epithelial cells surrounded by undifferentiated mesenchymal cells. Mullerian Inhibiting Substance Receptor (Misr2/Amhr2) expression is first detected in the Mullerian mesenchyme at around E13.5 both in males and in females (Arango et al., 2008). In male mice, secretion of MIS (also known as Anti-Mullerian Hormone or AMH) by the developing testes causes regression of the Mullerian ducts during embryonic days 14.5–15.5 (Jost, 1947; Josso et al., 1976). Regression of the male Mullerian ductal epithelium is mediated through non-cell autonomous paracrine signals emanating from the underlying Misr2+ mesenchymal cells in response to MIS, and is thought to be dependent on Wnt signaling and beta-catenin activity in the epithelium (Mullen and Behringer, 2014). The Mis/Misr2 (Amh/
Amhr2) pathway is highly specific to this process, since either ligand or receptor knockout mice present with identical phenotypes of persistent Mullerian duct syndrome (PMDS), a rare form of male pseudohermaphroditism in mice (Behringer et al., 1994; Mishina et al., 1996; Mishina et al., 1999) and humans (Imbeaud et al., 1994). It is thought that the narrow developmental window when Mullerian duct regression occurs is the only period when these Misr2+ mesenchymal cells are able to respond to MIS, beyond which further differentiation of the duct renders it insensitive to this inhibitory signal (Josso et al., 1976). Indeed, transgenic mice with constitutive overexpression of MIS, driven by a metallothionein-1 promoter, during the critical period of Mullerian duct formation displayed Mullerian agenesis and quickly lost all germ cells in the ovary after birth (Behringer et al., 1990).

In females, which do not express MIS during embryonic development, the fate of these subluminal Misr2+ mesenchymal cells remains unclear. In adult mice, expression of Misr2 is restricted to the myometrium, suggesting a common origin for both cell types (Arango et al., 2005; Arango et al., 2008); however, the lack of an inducible Misr2 reporter mouse has precluded a precise lineage tracing. Many cell types of the urogenital ridge primordium including the coelomic epithelium, mesonephric mesenchyme, and Wolffian duct epithelium are thought to contribute to the formation and development of the Mullerian duct as it further differentiates into the oviduct, uterus, cervix, and vagina (Fujino et al., 2009; Mullen and Behringer, 2014). In rodents, most of the differentiation of the uterine layers occurs postnatally; at birth, the uterus consists of a single layer of luminal epithelium surrounded by undifferentiated mesenchyme which later develops into myometrium and endometrial stromal cells, while the epithelium subsequently gains the ability to form endometrial glands though invagination at postnatal day (PND) 6–9 (Branham et al., 1985; Brody and Cunha, 1989). The timing of development of the endometrial stroma, and its contribution to the coordination of development of the myometrium and endometrial glands in early postnatal development are poorly understood. Mutations of genes which orchestrate early Mullerian mesenchyme development can have drastic consequences on female fertility and lead to Mullerian aplasia or uterine hypoplasia as observed in the Mayer-Rokitansky-Kuster-Hauser syndrome (Patnaik et al., 2015). Therefore, the pathways involved in early postnatal specification of the uterine compartments are critical to our understanding of Mullerian development and uterine factor infertility. Here, we characterize the persistence of subluminal Misr2+ mesenchymal cells beyond the embryonic period of sexual
differentiation, document their retained sensitivity to MIS neonatally, and characterize their critical role in the development of the endometrial stroma.

Results

Female mullerian subluminal mesenchyme maintains Misr2 expression and MIS sensitivity postnatally in rodents

To determine the fate of the Mullerian subluminal mesenchyme in the developing uterus, we sought to identify specific markers whose expression in that cell type persisted postnatally. Although the embryonic development of the Misr2+ Mullerian mesenchyme has been extensively studied (Jamin et al., 2002; Arango et al., 2008; Kobayashi et al., 2011), its early postnatal fate has not. Using lineage tracing in a Misr2-CRE/TdTomato reporter transgenic cross in C57BL/6 mice, we first confirmed that embryonic urogenital Misr2+ intermediate mesoderm gives rise to both the endometrial and the myometrial layers of the uterus, but not its epithelium (Figure 1—figure supplement 1A). Because Misr2-CRE is not inducible, any Misr2 expression during early development will result in permanent expression of the TdTomato reporter (Figure 1—figure supplement 1A). Therefore, to track further the Misr2+ cells in Mullerian mesenchyme, we conducted careful spatiotemporal studies using Misr2 RNA in situ hybridization (RNAish) from the embryonic period (E14-15) into postnatal life (Figure 1A). As expected, expression of Misr2 is restricted to the mesenchyme surrounding the Mullerian duct in both male and female urogenital ridges during embryonic development (E17-19) (Figure 1A). Postnatally, Misr2 expression becomes increasingly restricted to a thin band of subluminal mesenchyme, while being excluded from the epithelium and developing myometrium (Figure 1A, PND 0, PND 2) (Figure 1A, Figure 1—source data 1). Following differentiation of the functional layers of the uterus around PND 6 (Brody and Cunha, 1989), Misr2 expression commences to be detectable in the myometrium consistent with previous findings (Arango et al., 2008) (Figure 1A).

To evaluate the effect of MIS on the development of the uterus, we chose to use rats which have larger litters and display a similar spatiotemporal pattern of Misr2 expression (Figure 1—figure supplement 1D–E, Figure 1—source data 1). Furthermore, in rats, Misr2 expression is gradually attenuated in the PND1-6 period, both at the proximal (cervix) and at the distal (oviduct) ends of the developing uterine horns (Figure 1—figure supplement 1D) coinciding with the timing of expansion of the endometrial stroma, and the rise in secretion of MIS from the developing ovaries, which was measured in the rat serum by ELISA (Figure 1—figure supplement 1B and C). To evaluate the sensitivity of Misr2+ mesenchymal cells to MIS during this postnatal period, we treated rat pups with adeno-associated viral vectors (AAV9) (Pépin et al., 2015; Kano et al., 2017) delivering MIS at PND 1 (Figure 1B and Figure 2A). Administration of a single dose of AAV9-MIS (5E10 particles/pup) on PND 1 led to a robust induction (2.8 ± 0.7 μg/ml) of circulating exogenous MIS as measured by ELISA on PND6 (Figure 2B). Postnatal exposure to MIS led to an alteration in the appearance of the uterus by PND 6, and severe uterine hypoplasia by PND 20, suggestive of a failure of the uterus to develop beyond its perinatal state (Figure 2C). Histomorphological analyses of transverse uterine sections revealed smaller uteri with underdeveloped endometrial stromal layers and smaller lumina in MIS-treated rats compared to their sibling controls at all time points analyzed (PND 6, 10, and 20) (Figure 2C and D, Figure 2—source data 1).

Treatment with MIS prevented the gradual decrease of Misr2+ cells, and inhibited the expansion of the endometrial stroma normally observed by PND 6 (Figure 2E). For consistency and clarity, we will refer to these persistent Misr2+ subluminal mesenchymal cells in the MIS-treated animal as ‘inhibited progenitors’, although this function remains presumptive. In response to MIS, these inhibited putative progenitors expressed high levels of Smad6, a negative regulator of TGFβ signaling, and a previously reported canonical downstream target of MIS in the Mullerian mesenchyme (Figure 2E), suggesting MIS signaling was both operational and autonomous to these Misr2+ cells (Clarke et al., 2001; Mullen et al., 2018).

Interestingly, the endometrial stromal hypoplasia resulting from MIS exposure precluded later development of endometrial glands, as confirmed by absence of Foxa2 marker expression in immunofluorescence and qPCR (Figure 2—figure supplement 1A and B). However, the development of the circular myometrial layers was unaffected by exposure to MIS, as shown in the MIS-treated
transverse uterine sections by immunofluorescence, and qPCR analysis of smooth muscle markers such as smooth muscle actin (Acta2) and transgelin (Tagln), which remain similar at various time points between control and MIS exposed uteri (Figure 2—figure supplement 1C and D). Surprisingly, the inhibited progenitor cells expressed Acta2 ectopically (shown in red) as well as Vimentin (shown in green) in response to MIS on PND 6 (Figure 2F), suggesting a metaplastic effect of MIS.

Figure 1. Subluminal mesenchymal cells of postnatal uteri retain expression of Misr2. (A) RNAISH (RNA scope) analysis of Misr2 in transverse sections of male urogenital ridges at E 17.5, and in a time series of the developing uteri including E 18.5, E 19.5, PND 0, 2, and 6 in mice). Scale bars = 50 μm (n = 8 for PND6; n = 4 for >PND6). Number of mice analyzed per time point is presented in Figure 1—source data 1. Black arrows demarcate to the myometrial layer at PND 20. (B) Representative scheme of the Misr2 expression pattern in the developing uterus. Subluminal mesenchymal cells continue to express Misr2 in the postnally until around PND 6. We sought to investigate the fate of these postnatal Misr2+ subluminal cells, and their possible role as progenitor cells of the endometrial stroma.

DOI: https://doi.org/10.7554/eLife.46349.003

The following source data and figure supplement are available for figure 1:

Source data 1. Number of replicates per time point for the Misr2 in situ analysis in mice (Figure 1A) and in rats (Figure 1—figure supplement 1D–E).

DOI: https://doi.org/10.7554/eLife.46349.005

Figure supplement 1. Misr2 expression is gradually attenuated in the PND 1–6 period, coinciding with the timing of the rise in secretion of MIS.

DOI: https://doi.org/10.7554/eLife.46349.004
Figure 2. Misr2+ subluminal mesenchymal cells are susceptible to inhibition by MIS. (A) Rat pups were treated with AAV9-MIS (MIS) or empty vector control (CTL) on postnatal day 1 (PND 1) and euthanized at different developmental time points (B–F). Rats were used as the initial model organism since their litter sizes are bigger than mice. (B) MIS serum levels from control and AAV9-MIS treated rats on day 6 (n = 3 for both). (C) H&E sections from CTL and AAV9-MIS treated uteri on PND 3, 6, and 20. Endometrial glands are demarcated by black arrows on day 20. Scale bars = 100 μm. (D) Percentage of the endometrial stroma area (%), and luminal duct height of the CTL and MIS-treated uteri (Figure 2—source data 1). (E) Misr2 and Smad6 expression pattern by RNAish. Scale bars = 100 μm. (F) Smooth muscle α-actin (SMA) in red, and Vimentin (Vim) in green on CTL and AAV9-MIS treated uterine sections (PND 6, scale bars = 100 μm).

DOI: https://doi.org/10.7554/eLife.46349.006

The following source data and figure supplement are available for figure 2:

Source data 1. Data, number of replicates and p values of significance between the control and AAV9-MIS treated uterine samples for histomorphological analysis.

DOI: https://doi.org/10.7554/eLife.46349.008

Figure supplement 1. MIS treatment inhibits endometrial gland formation but not myometrial development.

DOI: https://doi.org/10.7554/eLife.46349.007
Figure 3. Single cell RNA sequencing of PND 6 uteri reveals distinct cell types and unique gene signatures in response to MIS treatment. (A) Rat pups were treated with empty vector control (CTL) or AAV9-MIS (MIS) on PND 1, and euthanized on PND 6 (n = 3 for both). Following whole-tissue dissociation, RNA isolated from single uterine cells, were barcoded and sequenced using inDROP. (B) t-SNE plot of unbiased clustering of uterine cells, where each color-coded cluster represents one cell type/state (only the main uterine parenchymal clusters are represented) (Figure 3—source data 1). (C) Schematic representation of the differential cellular composition of control and MIS-treated uteri. (D) t-SNE plot of unbiased clustering of uterine cells (dots) color-coded by treatment with CTL (orange) and MIS (blue) (Figure 3—source data 1). (E) Gene expression levels of representative cell-type-specific markers for each cluster overlaid on t-SNE plots (featureplot, color-coded arrow refers to cell type). (F) RNAish stains of representative cell-type markers in transverse uterine sections of empty vector control (CTL) and AAV9-MIS (MIS) treated mice at PND 6. Scale bars = 100 μm, same for all sections. Mouse tissues were used for validation purposes as the RNA in situ probes were readily available for mice and the effect of MIS was conserved among mice and rats. (G) Rat pups treated with AAV9-MIS (MIS) or empty vector (CTL) on PND 1 were euthanized at different developmental time points (PND3, 6, and 15), and their uteri were harvested for QPCR analysis of one representative marker for each cluster (n > 2, unpaired Student’s t test, mean ± SEM, *p<0.05, **p<0.01) (Figure 3—source data 3).

DOI: https://doi.org/10.7554/eLife.46349.009

The following source data and figure supplements are available for figure 3:

Source data 1. Related to Figure 3, Figure 3—figure supplements 1, 2 and 4; Figure 4, Figure 4—figure supplements 1, 2 and 3 and Table 1. Figure 3 continued on next page
Source data 2. Differentially expressed genes (MIS vs Control) in the myometrium of the developing rat uteri. DOI: https://doi.org/10.7554/eLife.46349.015

Source data 3. Related to Figure 3G, Figure 4—figure supplements 1D, 3D, 4E. DOI: https://doi.org/10.7554/eLife.46349.016

Figure supplement 1. Single-cell RNA sequencing analysis of the control and AAV9-MIS treated rat uterine cells. DOI: https://doi.org/10.7554/eLife.46349.010

Figure supplement 2. Single-cell RNA-seq reveals the cell atlas of the developing PND6 uterus. DOI: https://doi.org/10.7554/eLife.46349.011

Figure supplement 3. Single-cell RNA-seq reveals the cell atlas of the developing PND 6 uterus. DOI: https://doi.org/10.7554/eLife.46349.012

Figure supplement 4. The myometrium cluster can be sub-divided into three different cell types whose gene signatures are only weakly affected by MIS treatment. DOI: https://doi.org/10.7554/eLife.46349.013

Single Cell RNA sequencing of the PND 6 uterus uncovered an unexpected diversity of cell types in control and MIS-treated uteri

To understand how MIS dysregulates stromal differentiation, we followed the fate of the Misr2+ sub-luminal mesenchymal cells following MIS treatment using single-cell RNA sequencing (scRNAseq), based on droplet microfluidic sorting of single cells (inDROP) (Klein et al., 2015). We performed an enzymatic digestion of the whole uterus on PND 6 (Figure 3A), a time point at which the Misr2+ sub-luminal mesenchymal cells are almost completely gone in the normal uteri, but are retained in the MIS-treated ones (Figure 2E).

The uterine horns of three control (treated with 5E10 empty vector particles/pup on PND1) and three AAV9-MIS-treated animals (treated with 5E10 particles/pup on PND1) were recovered at PND 6 and digested in a cocktail of proteases into single-cell suspensions (Figure 3A). The inDROP libraries were sequenced, demultiplexed, normalized, and analyzed using the Seurat package in ‘R’, as previously described (Butler et al., 2018). The processed sample of 9801 cells clustered into 15 groups: outer stroma (1494), inner stroma (1081), myometrium (1172), inhibited progenitor (946), luminal epithelium (898), dividing mesenchyme (750), vascular endothelium (535), dividing epithelium (314), mesothelial (313), myeloid (297), erythroid (155), pericyte (139), lymphatic endothelium (54), and nerve cells (33), along with a low-information cluster (high % of mitochondrial genes) which was censored from further analysis (1620) (Figure 3—figure supplement 1A–C, Figure 3—source data 1). Cell identity of each cluster was assigned based on the presence of previously reported cell-type markers using the top 15 significantly enriched genes (by adjusted p-value) of the single cell analysis, summarized in Table 1. Markers include Smoc2 (Mucenski et al., 2019) for stromal cells; Ptn (Mucenski et al., 2019) for myometrial cells; Epcam and Wnt7a (Litvinov et al., 1997) (Miller and Sassoon, 1998) for luminal epithelium cells; Top2a (Whitfield et al., 2006) for proliferating cells, Cdh5 (Bhasin et al., 2010) for vascular endothelial cells; Wnt7a and Hmgb2 for dividing epithelium (Miller and Sassoon, 1998) (Stros et al., 2009); Msln for mesothelial cells (Chang and Pastan, 1996); Csf1r (MacDonald et al., 2010) for myeloid cells (Zilionis et al., 2019); Alas2 (Kaneko et al., 2014) for erythroid cells; Mcam (Barron et al., 2016) for pericytes; Lyve1 (Hirakawa et al., 2003) for lymphatic endothelium; and Sox10 (Nonaka et al., 2008) (Zeisel et al., 2018) for neuronal cells (Table 1). A heatmap of the top five genes for each cluster (by fold expression over average) is also presented in (Figure 3—figure supplement 2). The top two markers generated from the heatmaps were also analyzed by violin plots among 14 different clusters (Figure 3—figure supplement 3).

Subsequent analyses focused on the five clusters representing the functional layers of the PND 6 uterus including luminal epithelium, myometrium, inner and outer endometrial stroma, and a unique cluster of cells responding to MIS treatment (inhibited progenitor) (Figure 3B and C). To validate the gene signatures of these clusters, and their changes in response to MIS treatment, we selected one marker gene (Figure 3—figure supplement 1D) for each unique cluster, and confirmed its cell-type-specific expression pattern in transverse uterine tissue sections of control as well as treated mice uteri at PND 6 by RNAish (Figure 3E and F). Endometrial stromal cells were found to have two transcriptionally distinct cell types: inner stroma (Bmp7+) and outer stroma (Wifkkn2+) (Figure 3B,
Table 1. Unique gene signatures of the 14 different cell types (clusters) from the developing rat uteri on PND 6.

Gene markers revealed by single cell RNA sequencing, sorted by highest adjusted p-value with positive LogFc (Figure 3—source data 1). Clusters identities were assigned to different cell types by RNAish validation and/or manual literature review. Top 15 markers, citations, and associations are listed in the table. Selected markers were further validated in Figure 3.

| Cluster Identity         | Gene Markers                                                                 |
|--------------------------|-----------------------------------------------------------------------------|
| Outerstroma (1)          | RGD1305645 Lum Ngrn AC109891.2 Cd24 ** Hmgb2 Cd93 * Epac1 * (Litvinov et al., 1997) |
| Myometrium (2)           | Smc2c * Postn Cpxm2 ** Rn60_1_221_6.1 Epac1 * (Litvinov et al., 1997) Smn1 * Calu5 ** Uplfb1 * Tyrobp * Hba.a2 * Mcam ** Mmn1 ** Sox10 * (Nonaka et al., 2008) |
| Innerstroma (3)          | Dpt * NEWGENE_d21351 Tgbi * AAB80_70687_08.1 Wldc2 * (Mucenski et al., 2019) Top2a * (Whitfield et al., 2006) RGD1_310587 Cd24 * Msn ** (Chang and Pastan, 1996) Csf1r ** (MacDonald et al., 2010) LOC103_69438_55 Rglf1 * Lyve1 ** (Hirakawa et al., 2003) |
| InhibitedProgenitor (4)  | Cpe Col1a1 Plac8 Fgfr2 Wnt7a * (Miller and Sassoon, 1998) Mx67 * (Whitfield et al., 2006) Emcn * Cad1 * Fmod Lye2 * Hbb * Eln * Fli1 ** (Hirakawa et al., 2003) |
| Epithelium (5)           | Vcan * Prn * (Mucenski et al., 2019) Vcan * Ucn5b * (Mullen et al., 2018) Cldn3 Tubbb5 * Tie1 * Ki15 Cai1 Fti1 LOCI036948_55 Cd4a11 * Cldn5 * Egfl8 |
| Proliferating cells (6)  | Don * Thbs2 ** Fn1 * Ugt1a2 Krt8 * LOC10_03995_39 Pivap Kn8 * Dpp4 * Cybb * Alas2 * (Kaneko et al., 2014) Igfbp7 * Fgii2 * Cdh19 |
| Vascular endothelium (7) | Col4a5 * Col1a1 Apocd1 Bambi ** Cdh1 * Racgap1 Cai1 Mt1 Anxa3 Laptm5 * Ybx3 * Cspg4 ** Kfl4 * Alopaf12 |
| Dividing epithelium (8)  | Apoe Ogn (Mucenski et al., 2019) Cdh11 * Sgrn Tectd2 LOCI0_03803_16 Adgrh4 Wnt7a * (Miller and Sassoon, 1998) Igfbp6 Tmsb4x Hba.a3 * Abcc9 * Cdh5 * Lcam |
| Mesothelium (9)          | Osr2 Sparc Col6a3 * Kcnk3 Cldn4 * Prc1 * Plxnd1 Mtx2a Cbb Ctzb * Alox15 Epa1 Tbx1 Col5a3 |
| Myeloid (10)             | Tnfrsd21 Cxcl12 Tnfrs21 Igfbp5 Mx1 Cdk1 * Epsa1 * Mx1 Lox Lcp1 * Car2 Rga5 Scl45a3 Ofm12a |
| Erythroid (11)           | Adamts7 Igfbp5 Ncd2 Igzr Klf5 Depdc1 Esam * Wfcd2 Muc16 * Ptpc * Ahsp * Fox31 * Adgrg3 Metm |
| Pericyte (12)            | Slic28a7 Ccld80 Axn2 Pla2 Pla8 Elt1 * Smc2 Cyrr1 Dx5 Itm2a C1qa * Rbm38 My19 Sdpq Mpo * |
| Lymphatic endothelium (13)| Wfikko2 ** Gpc3 Vsm * Prx2 Dlx5 Kfl11 * Clec14a Sbスポーレン Sema3c C1qc * Lglas5 RGD1_504664 LOC10_09120_34 Plakha4 |
| Neuronal (14)            | Col6a3 * Igf10 Col6a2 * Alp1 Aldh2 Cepn1 * Adgrf5 Hmgb22 * (Stros et al., 2009) Fbln2 * Aif1 * Slic4a1 Acta2 * Rn50_1_043_5.2 Dib |

Table 1 continued on next page.
| Table 1 continued |
|-------------------|
| **Outer stroma (1)** | **Myometrium (2)** | **Inner stroma (3)** | **Inhibited Progenitor (4)** | **Epithelium (5)** | **Proliferating cells (6)** | **Vascular endothelium (7)** | **Dividing epithelium (8)** | **Mesothelium (9)** | **Myeloid (10)** | **Erythroid (11)** | **Pericyte (12)** | **Lymphatic endothelium (13)** | **Neuronal (14)** |
| *extracellular matrix, collagen or cytoskeleton related** validated new marker (in uterus) | *cell cycle or proliferation associated** implicated higher expression in vascular tissues | *endothelial associated** implicated during Mullerian duct regression in males **validated new marker (in uterus) | *epithelium associated** associated with epithelium | *endothelial associated** cell proliferation associated | *mesothelium associated or enriched** mesothelium specific | *myeloid associated** myeloid specific | *hemoglobin associated** fibroblast marker | *endothelial related** lymphatic endothelium associated | *neuronal related** (Zeisel et al., 2018) |

DOI: https://doi.org/10.7554/eLife.46349.024

Saatcioglu et al. eLife 2019;8:e46349. DOI: https://doi.org/10.7554/eLife.46349.024
C). Further subdivision of the myometrium cluster led to three distinct cell subtypes in the developing myometrial layer, all of which presented similar numbers of control and treated cells: inner myometrium (Myh11+), outer myometrium (Thbs2+), and interstitial (myofibril enriched) myometrium (Mfap5+) (Figure 3D–F, Figure 3—figure supplement 4, Figure 3—source data 2).

**MIS blocks the expansion and differentiation of an Misr2+ putative stromal progenitor**

We next focused on differential gene expression in response to MIS treatment using our dataset of 6811 control and 2990 MIS-treated cells. In our cell atlas, the control and treated uterine cell datasets were of similar quality, and had comparable distributions of unique molecular identifiers (UMI) and gene numbers (Figure 3D, Figure 3—figure supplement 1B, Figure 3A). While both the epithelial (CTL 9.63%, MIS 8.06%) and the myometrial (CTL 11.98%, MIS 16.72%) (Figure 3—figure supplement 1B–C, Figure 3—figure supplement 4) cell types were re-presented in similar proportions in both datasets, ‘inner’ (CTL 18.68%, MIS 3.28%) and ‘outer’ (CTL 15.64%, MIS 0.27%) endometrial stroma clusters (Figure 3—figure supplement 1B–C) were almost entirely composed of control cells unlike the ‘inhibited progenitor’ cluster, which was unique to the MIS treatment (Figure 3B–D, Figure 3—figure supplement 1B–C, Figure 4A, Figure 4—figure supplement 1). Misr2 expression was enriched only in the inhibited progenitor cluster (Figure 3C–D, Figure 4A) as previously observed by RNAish (Figure 2E). MIS stimulation caused the sub-luminal inhibited progenitor cells to persist longer and induced overexpression of genes related to the bone morphogenic protein and transforming growth factor beta (BMP/TGFβ) signaling pathways (Smad6, Bambi), epigenetic markers (Hdac4), and, strikingly, to express ectopically smooth muscle (Thbs2) and epithelial (Mx2) markers, reflecting the multipotent characteristics of the early Mullerian progenitors (Figure 3E–G, Figure 4A, Figure 4—figure supplement 1A–D, Table 1). QPCR analysis of these ectopically expressed genes revealed that the large differences observed at PND 6 diminished with time, and became less pronounced by PND 15 (Figure 3G, Figure 4A, Figure 4—figure supplement 1; Figure 4—figure supplement 2; Figure 4—figure supplement 1B, Figure 3—source data 3).

Cleaved caspase-3 histological staining of the MIS-treated uteri confirmed that the inhibited progenitor cells underwent apoptosis at approximately 9 days after treatment, whereas normally developing endometrial stromal cells were negative for the apoptotic marker (Figure 4—figure supplement 1E). QPCR and RNAish validation of differentially expressed genes in the stroma confirmed that both Wifkkn2 (‘outer stroma’), Bmp7 (‘inner stroma’) failed to be induced over time in the MIS treated group (Figure 3G), along with other markers such as Cpxm2 and Enpp2 (Figure 4—figure supplement 3A–D), consistent with the hypothesis that MIS prevented the subluminal progenitor cells from undergoing stromal specification and amplification; instead they eventually underwent apoptosis (Figure 4—figure supplement 1E).

**MIS disrupts gene expression in the luminal epithelium in a non-cell-autonomous manner**

Our results indicate that neonatal exposure to MIS induces changes in gene expression in the epithelial cell cluster as visible by the shifted treatment population in the t-SNE plot (Figure 3D, Figure 3—figure supplement 1B, Figure 4—figure supplement 4A). Even though expression of the basic luminal epithelial cell markers were not significantly different between control and MIS-treated cells (Ecad, Cd24, and Klf5) (Figure 4—figure supplement 4 A–E), differential gene expression analysis of the epithelial cluster based on treatment (CTL and MIS) revealed gene candidates whose expression was significantly changed by MIS treatment (Figure 4—figure supplement 4F–I) despite the lack of Misr2 expression in epithelial cells (Figure 1A,E). We confirmed that Id3 was downregulated in the MIS-treated epithelial cells (Figure 4—figure supplement 4H). Another intriguing gene expression pattern in response to MIS treatment was the downregulation of the epithelial cell marker Mxs2 at PND6, which coincides with its ectopic expression in the inhibited putative progenitor (Figure 3F–G (Mxs2), Figure 4A, Figure 4—figure supplement 4F). These results are consistent with MIS mediating the indirect repression of epithelial Mxs2 and Id3 through paracrine signals emanating from the Misr2+ mesenchymal cells, or the lack of normal endometrial stromal signals, which
Figure 4. MIS treatment blocks the differentiation of a putative progenitor cell, preventing endometrial stroma formation, which indirectly dysregulates epithelial cell development. (A) When treated with MIS, a unique population of Misr2+ subluminal putative progenitor cells are retained (inhibited progenitors), while the inner and the outer endometrial stromal layers fail to develop (representative scheme on the left). Note the differential expression pattern of stromal markers in the violin plots of the control and the MIS-treated uterine cells. See Figure 3 and Figure 4—figure supplements 1–3 for validation of these markers on tissue sections. (B) Diagrams of the unique receptor-ligand pairs present 1) between luminal epithelial cells and inner stromal cells (which are absent in MIS-treated uteri) (left), and 2) between the epithelial cells and the inhibited progenitor cells, (which are only present in the MIS-treated group).

DOI: https://doi.org/10.7554/eLife.46349.017

The following source data and figure supplements are available for figure 4:

**Source data 1.** Cell phone DB analysis.
DOI: https://doi.org/10.7554/eLife.46349.022

**Source data 2.** Differentially expressed genes (MIS vs Control) in the luminal epithelium of the developing rat uteri.
DOI: https://doi.org/10.7554/eLife.46349.023

**Figure supplement 1.** The inhibited progenitor cluster is only present in the MIS-treated uterus and corresponds to a subluminal mesenchymal cell.
DOI: https://doi.org/10.7554/eLife.46349.018

**Figure supplement 2.** Endometrial stromal layers fail to form when the putative progenitor cells are inhibited by MIS.
DOI: https://doi.org/10.7554/eLife.46349.019

**Figure supplement 3.** Single-cell RNA sequencing reveals the gene signature of uterine epithelial cells and a non-cell autonomous response to MIS.
DOI: https://doi.org/10.7554/eLife.46349.020

**Figure supplement 4.** Receptor-ligand interactions in the control and MIS-treated uterine atlases.
DOI: https://doi.org/10.7554/eLife.46349.021
in turn may prevent subsequent endometrial gland formation at later time points (Figure 4—figure supplement 4I, Figure 2—figure supplement 1A–D).

Finally, to survey the paracrine signaling between the inner stroma and epithelium and catalog how it may be disrupted by MIS treatment (inhibited putative progenitor and epithelium), we performed a comprehensive ligand/receptor analysis using the CellPhoneDB algorithm (Ventotermo et al., 2018) (Figure 4B, Figure 4—figure supplement 4, Figure 4—source data 1). Briefly, significantly expressed ligand/receptor pairs were systematically cataloged between each functional cell types (Figure 4B), revealing important developmental pathways dysregulated in MIS-treated uteri, such as Wnt and Igf2 signaling (Figure 4B, Figure 4—figure supplement 4, Figure 4—source data 1).

**Misr2+ putative progenitors are necessary for uterine development and fertility only during the first 6 days of life**

The timing of expression of Misr2 in the subluminal mesenchyme led us to hypothesize that limiting exposure to MIS during only the first 6 days of development could be sufficient to explain the observed long-term uterine hypoplasia. To test this hypothesis, we treated rat pups with recombinant MIS protein (rhMIS) during 6 days intervals (3 mg/kg) starting from days 1, 6, or 11 (Figure 5A). Consistent with this hypothesis, only when rats were treated during PND1-6 period were the uteri smaller than controls, at PND6, 20, 45, and even up to 8 months (Figure 5B,C,G). In contrast, when rhMIS was administered starting from PND6 or PND11, uterine hypoplasia was muted or absent, suggesting a narrow window of susceptibility with long-lasting consequences (Figure 5B). Therefore, only perinatal (PND1-6) administration of rhMIS completely phenocopied the continuous exposure phenotypes observed with AAV9-MIS, including lower percentage of endometrial stromal cells, smaller luminal ducts, and absence of glandular development (Figure 5B, Figure 5—figure supplement 1A) as confirmed by downregulation of Foxa2 expression and absence of glandular ducts (Figure 5D–E). Strikingly, this 6-day postnatal treatment was also sufficient to cause complete infertility later in adulthood (n = 3 per group, p<0.05) (Figure 5F). Analysis of the control and the 6-day rhMIS-treated uterine at a later time point (8 months) confirmed that the profound endometrial stromal hypoplasia persists in the adult (Figure 5G–H). In contrast, the ovaries fully recover from the short MIS inhibition of folliculogenesis (PND1-6) and display normal ovarian sizes and follicular composition at this timepoint (Figure 5H).

The impaired uterine development and infertility is unlikely to be secondary to ovarian suppression since folliculogenesis only starts reaching early pre-antral stages by PND6, and MIS treatment appears to have little effect on steroid hormones (E2 and P4) during that time (Figure 5—figure supplement 1B). Furthermore, as previously described (Kano et al., 2017), MIS inhibition of folliculogenesis by rhMIS is reversible, and while the MIS-treated PND1-6 ovaries showed an initial delay in folliculogenesis at early timepoints (PND20), it was resolved by PND 45 confirming no lasting impact on ovarian function (Figure 5—figure supplement 1C–D).

To confirm that the effect of MIS on the Misr2+ putative stromal progenitor was intrinsic to the uterus (and not the ovary), we treated gonadectomized rat pups with control or AAV9-MIS on PND2 (Figure 5—figure supplement 2A,B), which resulted in the same uterine hypoplasia phenotype by PND 10 (Figure 1C). Finally, to confirm that the signaling in the ‘inhibited progenitor’ was dependent on the canonical MIS receptor, we treated Misr2-deficient female mice (Misr2−/−) with AAV9-MIS, which failed to recapitulate the uterine hypoplasia phenotype (Figure 5—figure supplement 2B,C). Together, these results revealed a cell-autonomous effect of MIS in the subluminal mesenchyme, intrinsic to the uterus, and dependent on Misr2, in which progenitors normally specified to form endometrial stromal layers at PND1-6 are inhibited by MIS, leading to long-term infertility.

**MISR2+ subluminal mesenchymal cells are transiently present in the developing embryonic human uterus**

We sought to determine whether uterine subluminal mesenchymal cells expressing MISR2 are also present in the human female fetus preceding production of the ligand (MIS) by the ovary. We used paraffin-embedded archival tissue of human female reproductive tract from fetuses ranging from 22 weeks (wk) to 37 weeks of gestation. Using the adjacent fetal ovary tissue as a positive control for MISR2 RNAish, we analyzed the uterus at different developmental stages, revealing a
spatiotemporal pattern of expression strikingly similar to that of the rodents (Figure 6A–C). MISR2+ cells were present in the same location in the fetal uterus, directly adjacent to the lumen at 22 weeks of gestation and receded at later timepoints (24wk, 37wk), coinciding with the production of MIS by the human ovary, which is thought to begin at 24 weeks of gestation (Kuiri-Hänninen et al., 2011). To determine if candidate genes suspected to cause Mullerian aplasia or hypoplasia in humans (Nik-

**Figure 5.** Temporary treatment with MIS during only for the first 6 days of uterine developmental is sufficient to cause complete infertility in adulthood. (A) Rat pups were injected daily with recombinant MIS protein (3 mg/kg) (MIS), or saline control (CTL), from PND1-6, PND6-11, or PND11-17. (B) Uterine morphology was analyzed on PND45 with H and E stained transverse sections (n > 2). Scale bars are 100 μm. (C) Total uterus area, the percentage of the endometrial area, and the luminal duct height in CTL and MIS-treated (from PND1-6) were compared at PND20 and 45. (D) Foxa2 immunofluorescence (red) on CTL and MIS-treated uteri (from PND1-6) was analyzed at PND20. Scale bars = 50 μm. (E) Endometrial gland counts were compared in CTL and MIS-treated uteri (from PND1-6) at PND20 and 45 from H and E sections. (F) Cumulative pups per females in 3 months continuous mating studies of the control and MIS-treated rat uteri. (n = 3 both for the control and the treated, unpaired Student’s t test mean ± SEM, * (p<0.05), ** (p<0.01)). (G) Gross morphology of the CTL and the MIS-treated (PND1-6) uteri at 8 months of age. Scale bar = 0.5 cm. (H) Uterine transverse sections (top) and ovaries (bottom) of the control and MIS-treated rats at 8 months of age. CL stands for corpus luteum. Scale bars = 100 μm.

DOI: https://doi.org/10.7554/eLife.46349.025

The following source data and figure supplements are available for figure 5:

**Source data 1.** Data, number of replicates and p values of significance between the control and recombinant MIS-treated uterine samples for histomorphological analysis.

DOI: https://doi.org/10.7554/eLife.46349.028

**Figure supplement 1.** Neonatal exposure to MIS causes uterine hypoplasia but does not affect sex steroid levels or ovarian function.

DOI: https://doi.org/10.7554/eLife.46349.026

**Figure supplement 2.** Uterine hypoplasia in response to treatment with exogenous MIS does not require ovaries and is dependent on MISR2.

DOI: https://doi.org/10.7554/eLife.46349.027

Saatcioglu et al. eLife 2019;8:e46349. DOI: https://doi.org/10.7554/eLife.46349
(Zainal et al., 2011) may be present in the developing rat uterus, we analyzed their expression in our cell atlas, revealing the enrichment of several candidates within the ‘inhibited progenitor’ cluster (Figure 6D).
Discussion

Single-cell RNA sequencing of the PND6 uterus revealed that the subluminal Mullerian duct mesenchyme contains a previously uncharacterized cell type (Figure 7) that plays a crucial role in the specification of the endometrial stroma during neonatal uterine development. We hypothesize that these Misr2+ cells represent stromal progenitors, which normally gives rise to the inner and outer endometrial stromal layer around PND6 in mice and rats (Figure 1B). Surprisingly, these Misr2+ putative stromal progenitors retain sensitivity to inhibition by MIS postnatally, and can be reprogrammed to undergo apoptosis instead of developing into the endometrial stromal layers if exposed to MIS (Figure 7).

Although postnatal MIS exposure is no longer able to induce regression of the uterine luminal epithelium, its normal function in male fetuses (Jost, 1947), it does irreversibly block its ability to form endometrial epithelial glands. We speculate that this retained sensitivity to MIS in the female may be a vestigial pathway of the male, which is normally silenced in females prior to the emergence of secretion of MIS by the ovary. However, it is unlikely that MIS itself is an important developmental trigger regulating endometrial stroma development, since the uterus develops normally in both Mis and Misr2 knockout mice (Behringer et al., 1994)(Mishina et al., 1999) (Mishina et al., 1999).

The postnatal response of the Misr2+ putative progenitors to MIS provides some unique insights into the developmental pathways elicited during fetal Mullerian duct regression. The nascent fetal Mullerian duct is mesoeipithelial in origin, being derived from the invagination of the coelomic epithelium, and begins further differentiation into epithelium proper coincidentally with the timing of regression. Others have suggested that this epithelial differentiation may subsequently restrict the ability of the ductal cells to undergo the epithelial to mesenchymal transition characteristic of ductal regression (Allard et al., 2000). This raises the possibility that the Misr2+ mesenchyme in the neonatal female may be responding to MIS similarly to male urogenital mesenchyme, but that the neonatal epithelium is unable to regress in response to those signals. Supporting this interpretation of recapitulated mesenchymal regression is the ectopic expression of many of the same genes and
pathways previously identified in the regressing male fetal Mullerian duct (Bambi, Smad6, Wif1, etc.) (Mullen et al., 2018).

Even though gain of function MIS or MISR2 mutations have not been reported in women with Mullerian anomalies, the uterine hypoplasia observed in the present study is suggestive of Mayer-Rokitansky-Küster-Hauser syndrome (MRKH), also known as Mullerian aplasia which affects 1 in 4500 women (Nik-Zainal et al., 2011). Genes expressed in the Misr2+ putative progenitor cells in response to MIS treatment likely represent either pathways of Mullerian duct regression or of uterine endometrial stroma progenitor development. Therefore, we speculate that the markers described herein may represent candidate genes underlying developmental disorders of the Mullerian duct. Efforts to identify causative genes within regions of copy number variation in patients affected with Mullerian aplasia have turned up candidate genes such as KHDRBS2, and GFRA1 (Nik-Zainal et al., 2011), which we see uniquely expressed in the ‘inhibited progenitor’ cluster (Figure 6D). Similarly, both Gata3 which causes hypoparathyroidism, sensorineural deafness, renal anomaly (HDR) syndrome with uterine hypoplasia (Van Esch et al., 2000) and Fgfr2, which causes disorders of sexual dimorphism in males (Bagheri-Fam et al., 2015; Barseghyan et al., 2018), and decidualization defects in females (Filant et al., 2014), are highly expressed in the inhibited MISR2+ progenitors (Figure 6D).

The importance of the endometrial stroma in the formation of endometrial glands and fertility has been demonstrated in multiple mouse models such as Wnt4 mutant mice, and neonatal diethylstilbestrol (DES) treatments, both of which carry phenotypes of endometrial glandular dysplasia also observed in our rodents with postnatal exposure to MIS (Herbst et al., 1980; Medlock et al., 1988; Hayashi et al., 2011; Prunskaite-Hyyryläinen et al., 2016). These mouse models display endometrial stromal hypoplasia, which precludes glandular development as a result of the disruption of Wnt pathways and the communication between stromal and epithelial compartments. Our single-cell transcriptomic analysis identified distinct inner and outer endometrial stromal layers with molecular signatures that might presage specialized stromal functions, such as regulation of the adjacent epithelium or myometrium. A comprehensive characterization of such paracrine signals across the cell types of our control and MIS-treated uterine atlases using the CellPhoneDB algorithm (Vento-Tormo et al., 2018) revealed the immense complexity of those cellular interactions, and their dysregulation by MIS (e.g. Wnt signaling, Figure 4B). MIS treatment is likely especially disruptive to the interaction between the inner endometrial stroma and adjacent luminal epithelium, as seen by the absence of expression of Bmp7, and coincidental downregulation of Msx2 in those cell types, respectively, which have been previously implicated in the coordination of endometrial gland formation in the uterus (Phippard et al., 1996; Kodama et al., 2010; Yin et al., 2015) and decidualization defects (Daikoku et al., 2011; Monsivais et al., 2017). The nature of the paracrine signals emanating from the inner stroma regulating epithelial development, and their dysregulation during MIS treatment, including the ephrin, notch, Igf, Tnf, Mdk/Ptn, Tyro3, and Fn1 pathways (Figure 3, Figure 3—figure supplement 4), should be systematically investigated in future studies.

Furthermore, the involvement of premature exposure of the developing Mullerian ducts to MIS in disorders of sexual differentiation of the female is not fully appreciated (Chen et al., 2014; Van Batavia and Kolon, 2016). Moreover, the recent identification of an Misr2+ subepithelial adult endometrial stem cell suggests that some neonatal endometrial stromal sprogenitor may persist into adulthood, where they could play a role in endometrial homeostasis and repair (Yin et al., 2019). Interestingly, we have recently reported an increased incidence of preterm birth in PCOS patients with high circulating MIS (Hsu et al., 2018) raising the possibility of a causative link between high MIS exposure and uterine dysfunction. Conversely, the complete infertility resulting from a short treatment with MIS could have useful applications in the veterinary settings where it may be used as a permanent contraceptive that does not affect ovarian function (Hay et al., 2018).

Finally, given our findings that MIS is a potent inhibitor of MISR2+ putative endometrial stromal progenitors during uterine development, and that this cell type is likely also active in fetal human uteri, it would be of interest to explore possible clinical applications of MIS, or related pathways, in the context of Mullerian development pathologies, uterine infertilities, and endometrial stromal cancers, should these pathways become reactivated in those tumors (Chiang and Oliva, 2013).
### Key resources table

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Genetic reagent (M. muculus)     | B6;129S7-Amhr2tm3 (cre)Bhr/Mmnc | PMID: 12368913 | RRID_, MGI:3042214 | Dr. Richard R Behringer, MD Anderson Cancer Center |
| Genetic reagent (M. muculus)     | C57BL/6-Tg(UBC-GFP)30Scha/J | Jackson Laboratory | stock #004353 | Hongkui Zeng, Allen Institute for Brain Science |
| Genetic reagent (M. muculus)     | FVB/NCrI | Charles River | #207 |
| Genetic reagent (Rat)            | Sprague Dawley | Envigo |
| Peptide, recombinant protein     | LR-MIS | (Pépin et al., 2013) |
| Recombinant DNA reagent          | AAV9-LRMIS | (Pépin et al., 2015) |
| Antibody                         | Smooth muscle alpha action (SMA) (Rabbit polyclonal) | Abcam | #5694 | (1:300), IF |
| Antibody                         | Vimentin (rabbit monoclonal) | Abcam | #92547 | (1:300), IF |
| Antibody                         | Foxa2 (rabbit polyclonal) | LifeSpan Biosciences | #138006 | (1:500), IF |
| Antibody                         | Cleaved caspase-3 (rabbit polyclonal) | Cell signaling | #96615 | (1:200), IF; (1:500) IHC |
| Antibody                         | E-cadherin (Cdh1) (rat monoclonal) | Invitrogen | #13–1900 | (1:200), IF |
| Antibody                         | Alexa flour 488 donkey anti rat IgG | Invitrogen | #A21208 | (1:500) |
| Antibody                         | Alexa flour 555 donkey anti rabbit IgG | Invitrogen | #A31572 | (1:500) |
| Antibody                         | Alexa flour 568 anti rabbit IgG | Invitrogen | #A10042 | (1:500) |
| Commercial assay or kit          | RNA scope 2.5 HD red detection kit | ACD bio | #322360 |
| Commercial assay or kit          | the target retrieval and protease plus reagents | ACD bio | #322330 |
| Commercial assay or kit          | MIS commercial ELISA | Beckmen | #A73818 |
| Commercial assay or kit          | REDExtract-N-Amp Tissue PCR Kit | Sigma | #SLBT8193 |
| Other                            | Bambi (M. muculus) (NM_026505.2) | ACD bio | #523071 | commercial probe |
| Other                            | Bmp7 (M. muculus) (NM_007557.3) | ACD bio | #407901 | commercial probe |
| Other                            | CD24a (M. muculus) (NM_009846.2) | ACD bio | # 432691 | commercial probe |
| Other                            | Cpxm2 (M. muculus) (NM_018867.5) | ACD bio | # 559759 | commercial probe |

Continued on next page
Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
---|---|---|---|---|
Other | Enpp2 (M. muculus) (NM_001136077.1) | ACD bio | # 402441 | commercial probe |
Other | Hdac4 (M. muculus) (NM_207225.1) | ACD bio | # 416591 | commercial probe |
Other | Misr2 (Amhr2) (M. muculus) (NM_144547.2) | ACD bio | # 489821 | commercial probe |
Other | Misr2 (Amhr2) (Rat) (NM_030998.1) | ACD bio | # 517791 | commercial probe |
Other | Misr2 (Amhr2) (Human) (NM_020547.2) | ACD bio | # 490241 | commercial probe |
Other | Msx2 (M. muculus) (NM_013601.2) | ACD bio | # 421851 | commercial probe |
Other | Myh11 (M. muculus) (NM_001161775.1) | ACD bio | # 316101 | commercial probe |
Other | Smad6 (M. muculus and Rat) (NM_011009002.2) | ACD bio | # 517781 | commercial probe |
Other | Thbs2 (M. muculus) (NM_011581.3) | ACD bio | # 492681 | commercial probe |
Other | Wifkn2 (M. muculus) | ACD bio | # 531321 | commercial probe |
Software, algoritm | R | R Project for Statistical Computing | | https://scicrunch.org/resolver/SCR_001905 |
Software, algoritm | BZ-X800 analysis software | Keyence | | https://www.keyence.com/landing/microscope/lp_fluorescence.jsp |
Software, algoritm | GraphPad Prism, version 7 | Graphpah | | |

**Animals**

This study was performed in accordance with experimental protocols 2009N000033 and 2014N000275 approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee. Strains of Sprague–Dawley (purchased from Envingo) and Friend leukemia virus B (FVB) (purchased from Charles River Laboratories) were used for rat and mouse experiments, respectively. Misr2/Amhr2-Cre knock-in mice were purchased from the Mutant Mouse Regional Resource Centers (MMRRC) (strain B6;129S7-Amhr2tm3(cre)Bhr/Mmnc, backcrossed with C57BL/6J) (Jamin et al., 2002). Tail genotyping of the Misr2-cre knock-in and WT mice were done with REDExtract-N-Amp Tissue PCR Kit (Sigma, #SLBT8193) with the previously described sets of primers (Jamin et al., 2002).

**AAV9-MIS and recombinant protein treatment**

The adeno-associated virus serotype 9 (AAV9) gene therapy vector was used for sustained delivery of a higher concentration of human MIS analog (LR-MIS) as described (Pépin et al., 2015). To test the effect of continuous MIS exposure on uteri, rats or mice were injected subcutaneously with AAV9-recombinant human LR or RF MIS (AAV9-MIS) on postnatal day 1, and their uteri were harvested at different time points for histological analysis (5E10 particles/pup). Blood was collected by cardiac puncture at endpoint, and centrifuged at 900 × g for 10 min at room temperature from control and AAV9-MIS-treated female rat pups on PND3, 5, 6, 10, 15, and 30 (n > 2). To validate the RNA scope markers on tissue sections, mice were injected with AAV9-MIS on PND 1 (1E10 particles/
pup), and sacrificed on PND 6 (n = 3 both for the control and the treated). For each time point, the uteri were cut radially in halves. One half was fixed in formalin for histological analysis and immunohistochemistry, the other half was flash-frozen for RNA isolation and qPCR analyses. In mice, the paraffin-embedded fixed tissue was sectioned for RNAiSh analysis, while in rats it was used for histomorphological analyses.

To test the window of sensitivity to exogenous MIS during uterus development, rats were injected subcutaneously with a human recombinant MIS (LR-MIS) protein (Pépin et al., 2013) daily (3 mg/kg/day) for 6 days starting from PND1-6, PND6-11, or PND11-17 (Figure 5A). Uteri of rat pups injected from PND1-6 were harvested and fixed on 20, and 45 (for PND20, n = 2 for control, n = 3 for treated, for PND45 n = 2 both for the control and the treated). Uteri of the rat pups injected from PND6-11, or PND11-17, were harvested and fixed on PND45 (n > 2 for all) (Figure 5A).

To rule out the involvement of ovarian hormones as a contributor to the MIS-induced uterine hypoplasia, rat pups were gonadectomized two days after birth (n = 4), prior to receiving MIS treatment (Figure 5—figure supplement 2A–B). For gonadectomy, the rat pups were anesthetized using iso-flurane. Bilateral longitudinal incisions were made in the mid dorsal line through the skin and musculature one-third the distance between the base of the tail and the neck, directly over the position of the ovary. The ovaries together with the oviducts were extruded through the incision via the ovarian fat pad. The ovarian vasculature was ligated between the oviduct and uterine horn and the ovaries and oviducts were resected. The muscle layer was closed with silk sutures, and the outer skin was closed with a single metal clip. The rats were then kept warm until they had completely recovered from the anesthesia. Analgesia was provided for 3 days with Carprofen PO. Two of the rat pups were treated with AAV9-MIS, while the controls were treated with empty vector (SE10 particles, subcutaneously, n = 2 both for control and treated) 6 hr after the surgery. The pups were then euthanized on PND10, and their uteri were fixed for histomorphological analysis (Figure 5—figure supplement 2A–B).

Misr2cre/cre transgenic mice
To verify that the MIS Receptor 2 (Misr2) is the mediator of the uterine phenotype caused by exogenous MIS, Misr2cre/+ and Misr2cre/cre transgenic mice (Jamin et al., 2002) were treated with empty vector or AAV9-MIS (5E10 particles, subcutaneously) on day 1 and their uteri were analyzed on PND20 (Figure 5—figure supplement 2C–D) (n = 2 for Misr2cre/+ , n = 1 for Misr2cre/cre . Misr2cre/cre males had retained Mullerian ducts confirming the loss-of-function of the Misr2 (Jamin et al., 2002).

ELISA
The Beckman AMH ELISA (Beckman, #A73818), which can detect both endogenous murine MIS and exogenous human MIS secreted by the AAV9-MIS infected muscles was used to measure the serum MIS levels. To detect the murine endogenous MIS levels during the developmental time span of rat females, serum from control PND1, 4, 6, and 20 rats, as well as AAV9-MIS-treated rats on PND six were measured by ELISA (n = 3 for PND4, 6 and 20, and n = 2 for PND 1, n = 3 for AAV9-MIS treated rat).

Murine Estradiol and Testosterone serum levels were measured with specific ELISAs at the Ligand Assay and Analysis Core of the Center for Research in Reproduction at University of Virginia School of Medicine under a cooperative agreement (The core is supported by the Eunice Kennedy Shriver NICHD/NIH (NCTR), Grant P50-HD28934). (n = 3 for PND3 and 30 control and treated, and PND 5 control; n = 2 for PND five treated; PND6, 10, 15 control and treated animals).

Fertility tests
Sprague–Dawley rats were injected subcutaneously with 3 mg/kg/day of recombinant MIS (LR-MIS) or 20 μl saline (vehicle control) from PND1-6. One MIS-treated and one sibling control female were caged with one experienced breeder male (n = 3 cages) at 6 weeks of age. The male was separated from the cage after pregnancy was identified and returned after the pups were weaned. The total number of pups and litters from each female was monitored for a period of 4 months.
Histology, immunofluorescence (IF), immunohistochemistry (IHC) and RNA in situ hybridization

Dissected uteri and ovaries were fixed in 4% (wt/vol) paraformaldehyde at 4°C (for histology and immunofluorescence) or in 10% neutral buffered formalin at room temperature overnight (for RNAISH). Tissues were embedded in paraffin blocks in an automated tissue processor (Leica #TP1020). 5 μm transverse uterine sections from the middle of the uterine horn (i.e ‘b’ in Figure 1—figure supplement 1D) were used for hematoxylin and eosin (H&E) staining, immunofluorescence (IF), and RNAISH using the RNA scope (ACD bio) system. Archival human fetal tissue sections were provided by the Massachusetts General Hospital, Gynecological Pathology Department through an IRB approved protocol (IRB 2007P001918).

Tissue sections were rehydrated for IF in an alcohol series after deparaffinization in xylene. Antigen retrieval was performed by parboiling in 10 mM sodium citrate (pH 6.0), cooling at room temperature, blocking in 3% bovine serum albumin (BSA) in Tris-buffered solution (TBS) for 1 hr, followed by three washes (10 min each) in TBS and the sections incubated in primary antibody overnight at 4°C. For double-labeling, the slides were blocked after washes, and then incubated with a second primary antibody overnight at 4°C. The sections were then incubated in fluorescently conjugated secondary antibodies (Alexa Fluor 555-conjugated donkey anti-rabbit IgG antibody, #A31572; Alexa Fluor 488-conjugated donkey anti-rabbit IgG, #A21206) for one hour at room temperature and cover-slipped with vectashield mounting medium with DAPI (Vector Laboratories #NC9265087). For immunohistochemistry (IHC), Dako EnVision + System horseradish peroxidase (HRP) Labeled Polymer Anti-Rabbit was used as the secondary antibody (#K4002), and the HRP signal was detected using the DAKO detection system (Dako, #K5007). Antibody dilutions for IF and IHC were as follows: Smooth muscle alpha action (SMA) (1:300, abcam, #5694), Vimentin (1:300, abcam, #32547), Foxa2 (1:500, LifeSpan Biosciences, #138006, 1:500), cleaved caspase-3 (1:50, cell signaling, #9661S), E-cadherin (Cdh1) (1:200, Invitrogen #13–1900).

RNAISH was performed with the manual RNAscope 2.5 HD Reagent Kit (RED) (ACD Bio, #322350) following the manufacturer’s instructions as previously described (Wang et al., 2012). The tissue sections were hybridized with pre-designed or custom-designed probes spanning mRNAs of the target genes (see Table S1 for accession number, target region, and catalog number of each gene) in the HybEZ hybridization oven (ACD Bio) for 2 hr at 40°C, following deparaffinization in xylene, dehydration, peroxidase blocking, and heat-induced epitope retrieval by the target retrieval and protease plus reagents (ACD bio, #322330). The slides were then processed for standard signal amplification steps, and a red chromogen development was performed using the RNAscope 2.5 HD (Red) detection Kit (ACD Bio, #322360). The slides were then counterstained in 50% hematoxylin (Dako, #S2302) for 2 min, air-dried and coverslipped with EcoMount.

Histomorphological analysis and quantification of RNA-scope images

Middle sections (‘b’ in the scheme of Figure 1—figure supplement 1D) of control and MIS-treated rat uteri were stained with H and Es for histomorphological analyses, which were conducted at different developmental time points (Figure 2—source data 1, Figure 5—source data 1). Luminal duct height, area of the whole uterus, and area of the endometrium were calculated from the transverse sections using the image J software. For Figure 2, n = 3 for PND3 control and treated; n = 2 for PND6, 20 control and treated, n = 1 for PND10 control and treated samples. For Figure 4, n = 2 for the PND20 control; PND45 control and the treated; n = 3 for the treated PND20 sample (Figure 2—source data 1).

Human fetal tissue sections were imaged by the Keyence BZ-X800 microscope at 20x resolution, and the RNAISH stains were auto-quantified by BZ-X800 analysis software. Approximately 60 images were obtained per stained section, and stitched together for the top panel of Figure 6a. 5 random 20x images were selected per time point for analysis, and areas of red RNA scope dots (Misr2 transcripts amplified by RNA-scope) were detected and labeled based on hue (see red dots on the bottom section of Figure 4a, labeled as ‘enhanced Misr2’). Total cell area was calculated by setting the masked area as the hematoxylin-stained region. RNAish dots/total area were auto-calculated by the same settings in 5 random 20X sections of human fetal tissues from 20, 22, and 37 weeks of gestation, n = 1 for each time point.
Quantitative PCRs

Total RNA was extracted from the uteri of control and AAV9-MIS treated rats at different time points (Figure 3—source data 3) using the Qiagen RNA extraction kit. For all the samples, cDNA was synthesized from 500 ng total uterine RNA using SuperScript III First-Strand Synthesis System for RT-PCR according to manufacturer’s instructions using random hexamers (Invitrogen, # 18080–051). The primers were designed to span the exon-exon junctions of the target genes (see Figure 3—source data 3 for complete list of primers) to avoid genomic DNA contamination. Expression levels relative to 18S (for Acta2) and Gapdh (for all the other genes analyzed) were calculated by using cycle threshold (Ct) values logarithmically transformed using the $2^{-\Delta Ct}$ function and the average value of the relative expression levels were normalized to PND three control set; and fold changes were calculated relative to PND three control time point with three technical replicates per sample. For Acta2, Tgln, and Foxa2 expression levels were normalized to PND six control set. Sample sizes and p values for each gene and time point are listed in Figure 3—source data 3.

Generation of single cell (sc) suspension for scRNAseq

Newborn rats (PND1) were injected with 5E10 particles of AAV9-MIS (N = 3) or AAV9 empty particle controls (N = 3). On PND6, rat pups were sacrificed and the uterine tissue was microdissected, taking care to exclude the oviduct, cervix, and ureter. Both uterine horns from each animals (N = 3 per group) were combined and placed in 5 mL of dissociation medium (82 mM Na$_2$SO$_4$, 30 mM K$_2$SO$_4$, 10 mM Glucose, 10 mM HEPES, and 5 mM MgCl$_2$ - 6H$_2$O, pH 7.4) containing 15 mg of Protease 23 (Worthington), 100 U Papain with 5 mM L-Cysteine and 2.5 mM EDTA (Worthington), and 1333 U of DNase 1 (Worthington) prewarmed to 34°C. The samples were placed on a rocker at 34°C for 15 min. The medium was then removed with a pipette and replaced with 5 mL chilled (4°C) stop medium (dissociation medium containing 0.025% BSA) supplemented with 0.5 mg trypsin Inhibitor and 0.5 mg ovomucoid protease Inhibitor. Samples were triturated 10 times with a 5 mL pipette, then 10 times with a 1000 μl micropipette, and finally filtered through a prewetted 100 μm filter. Filtered samples were spun at 1000 g for 10 min, and the cell pellet was resuspended in 1 ml of stop solution with 267 U of DNase. This step was repeated twice. Ten microliters was removed from each sample and combined with trypan blue to assess viability and concentration of cells. The cell mixture was spun a final time and resuspended in stop solution containing 20% Optiprep (Sigma) to a concentration of 150,000 cells/mL for inDrop sorting.

Single-cell RNA sequencing (inDrop) inDrop microfluidic sorting was performed as previously described (Hrvatin et al., 2018) generating two libraries of approximately 5000 cells from each combined (N = 3 rats) cell suspensions (control and MIS). Transcripts were processed as previously described and samples were sequenced on a NextSeq 500 (illumina) in a single combined lane (Hrvatin et al., 2018).

Data analysis of scRNAseq

The analysis of the demultiplexed data was performed using the Seurat package in ‘R’ (Butler et al., 2018). Filtering parameters were set to remove cells with fewer than 200 genes, and those with more than 3000 genes and/or 10,000 UMIs from the dataset. Dataset included 6811 control cells, and 2990 MIS treated cells which were jointly normalized. The Pearson correlation coefficient of UMI and nGene across the dataset was 0.97. Principal component analysis was performed using 20 dimensions and FindClusters parameters were set at k.param = 30, k.scale = 25, and prune. SNN = 0.0667 with a resolution of 0.6 using 5346 variable genes. Data set and R codes are presented in Figure 3—source data 1. For differential expression analysis of the myometrium and the epithelial cell clusters, data sets are presented in Figure 3—source data 2 and Figure 4—source data 2.

CellPhoneDB analysis

CellPhoneDB predicts signaling between cell clusters through analyzing co-expression of known Human receptors and secreted proteins. We downloaded ortholog information for Rat (Rnor_6.0) and Human (GRCh38.p12) from ENSEMBL (Release 95). For non one-to-one orthologs, we assigned the maximum of gene expression values for all Rat to Human mappings. CellPhoneDB was
subsequently run using default parameters (Vento-Tormo et al., 2018). The resulting data set is presented in Figure 4—source data 1.

Statistical analysis

For serum MIS ELISA measurements of the control rats, two-way ANOVA analysis was used. For the serum ELISA measurements of the control and the treated rats on PND6, the histomorphology, and the staining analyses, unpaired Student’s t test was used to compare the control and the treated samples using the Prism software (Graphpad version 8.0). p values are presented in Figure 2—source data 1, and Figure 3—source data 3, and Figure 5—source data 1.

Acknowledgements

We thank Bernardo Sabatini for his constructive feedback and assistance with the scRNAseq experiments. We acknowledge Abigail Alexander, Raghav Mohan, Selena Yuan, in performing histological stains. We also thank Nobuhiro Takahashi, Yi Li, Caroline Coletti, Nicole Foxworth, Ryo Hotta, and Sarah Mustafa Eisa for their technical help. This study was funded in part by Huizing Fellowship (HDS), Grant MG14-S06R from the Michelson Found Animal Foundation (to DP, PKD, and GG); a Sudna Gar Fellowship (DP); the Massachusetts General Hospital Executive Committee on Research (ECOR) (DP and PKD); and royalties from the use of the MIS ELISA in infertility clinics around the world.

Funding

| Funder                               | Grant reference number | Author                          |
|--------------------------------------|------------------------|---------------------------------|
| Michelson Prize and Grants           | MG14-S06R              | Patricia K Donahoe              |
|                                      |                        | David Pépin                     |
|                                      |                        | Guangping Gao                   |
| Huiying Fellowship                   |                        | Hatice Duygu Saatcioglu         |
| Sudna Gar Fellowship                 |                        | David Pépin                     |
| Massachusetts General Hospital        |                        | Patricia K Donahoe              |
|                                      | Massachusetts General  | David Pépin                     |
|                                      | Hospital Executive     |                                 |
|                                      | Committee on Research  |                                 |
|                                      | (ECOR)                 |                                 |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

Hatice Duygu Saatcioglu, Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing; Motohiro Kano, Data curation, Formal analysis, Validation, Investigation, Methodology; Heiko Horn, Data curation, Software, Formal analysis, Validation, Writing—original draft, Writing—review and editing; Lihua Zhang, Data curation, Validation, Methodology; Wesley Samore, Resources, Data curation, Formal analysis, Investigation; Nicholas Nagykery, Resources, Investigation, Methodology; Marie-Charlotte Meinsohn, Formal analysis, Validation, Investigation, Writing—review and editing; Minsuk Hyun, Resources, Formal analysis, Methodology; Rana Suliman, Validation, Investigation; Joy Poulo, Data curation, Software, Formal analysis, Validation, Methodology; Jennifer Hsu, Formal analysis, Investigation, Methodology; Caitlin Sacha, Data curation, Formal analysis, Methodology, Writing—review and editing; Dan Wang, Conceptualization, Resources, Methodology; Guangping Gao, Conceptualization, Resources, Supervision; Kasper Lage, Resources, Software, Supervision, Project administration; Esther Oliva, Conceptualization, Data curation, Supervision, Investigation; Mary E Morris Sabatini, Conceptualization, Investigation, Methodology; Patricia K Donahoe, Conceptualization, Supervision, Funding acquisition, Project administration, Writing—review and editing; David Pépin, Conceptualization, Data curation, Formal analysis, Supervision, Funding
acquisition, Validation, Investigation, Visualization, Writing—original draft, Project administration, Writing—review and editing

**Author ORCIDs**

Hatice Duygu Saatcioglu [https://orcid.org/0000-0003-2210-0005](https://orcid.org/0000-0003-2210-0005)

Motohiro Kano [https://orcid.org/0000-0002-5443-0175](https://orcid.org/0000-0002-5443-0175)

Heiko Horn [https://orcid.org/0000-0003-4898-0557](https://orcid.org/0000-0003-4898-0557)

Jennifer Hsu [https://orcid.org/0000-0001-6928-2585](https://orcid.org/0000-0001-6928-2585)

David Pépin [https://orcid.org/0000-0003-2046-6708](https://orcid.org/0000-0003-2046-6708)

**Ethics**

Human subjects: Human fetal tissue sections were procured by the Massachusetts General Hospital, Gynecological Pathology Department through The Institutional Review Board (IRB) approved protocol (#IRB 2007P001918).

Animal experimentation: This study was performed in accordance with experimental protocols 2009N000033 and 2014N000275 approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee.

**Decision letter and Author response**

Decision letter [https://doi.org/10.7554/eLife.46349.035](https://doi.org/10.7554/eLife.46349.035)

Author response [https://doi.org/10.7554/eLife.46349.036](https://doi.org/10.7554/eLife.46349.036)

**Additional files**

**Supplementary files**

- Transparent reporting form
  DOI: [https://doi.org/10.7554/eLife.46349.031](https://doi.org/10.7554/eLife.46349.031)

**Data availability**

Sequencing data have been deposited in OSF platform, the link is as follows: [https://osf.io/27hej/](https://osf.io/27hej/).

The following dataset was generated:

| Author(s) | Year | Dataset title | Dataset URL | Database and Identifier |
|-----------|------|---------------|-------------|-------------------------|
| Saatcioglu HD, Kano M, Horn H, Joy MP, Kasper L, Morris Sabatini ME, Donahoe PK, Pépin D | 2019 | Single-cell sequencing of neonatal uterus reveals an endometrial stromal progenitor indispensable for female fertility | [https://osf.io/27hej/](https://osf.io/27hej/) | Open Science Framework, 27hej |

**References**

Allard S, Adin P, Gouédard L, di Clemente N, Josso N, Orgebin-Crist MC, Picard JY, Xavier F. 2000. Molecular mechanisms of hormone-mediated müllerian duct regression: involvement of beta-catenin. *Development* **127**: 3349–3360. PMID: 10887090

Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK, Teixeira J. 2005. Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. *Developmental Biology* **288**:276–283. DOI: [https://doi.org/10.1016/j.ydbio.2005.09.045](https://doi.org/10.1016/j.ydbio.2005.09.045), PMID: 16256976

Arango NA, Kobayashi A, Wang Y, Jamin SP, Lee HH, Orvis GD, Behringer RR. 2008. A mesenchymal perspective of müllerian duct differentiation and regression in Amhr2-lacZ mice. *Molecular Reproduction and Development* **75**:1154–1162. DOI: [https://doi.org/10.1002/mrd.20858](https://doi.org/10.1002/mrd.20858), PMID: 18213646

Bagheri-Fam S, Ono M, Li L, Zhao L, Ryan J, Lai R, Katsura Y, Rossello FJ, Koopman P, Scherer G, Bartsch O, Eswarakumar JV, Harley VR. 2015. FGFR2 mutation in 46,XY sex reversal with craniosynostosis. *Human Molecular Genetics* **24**:6699–6710. DOI: [https://doi.org/10.1093/hmg/ddv374](https://doi.org/10.1093/hmg/ddv374), PMID: 26362256

Barron L, Gharib SA, Duffield JS. 2016. Lung pericytes and resident fibroblasts: busy multitaskers. *The American Journal of Pathology* **186**:2519–2531. DOI: [https://doi.org/10.1016/j.ajpath.2016.07.004](https://doi.org/10.1016/j.ajpath.2016.07.004), PMID: 27555112
Barseghyan H, Symon A, Zadikyan M, Almalvez M, Segura EE, Eskin A, Bramble MS, Arboleda VA, Baxter R, Nelson SF, Delot EC, Harley V, Vilain E. 2018. Identification of novel candidate genes for 46,XY disorders of sex development (DSD) using a C57BL/6J-Y POS mouse model. Biology of Sex Differences 9:8. DOI: https://doi.org/10.1186/s13293-018-0167-9, PMID: 29378665

Behringer RR, Cate RL, Froelick GJ, Palmiter RD, Brinster RL. 1990. Abnormal sexual development in transgenic mice chronically expressing müllerian inhibiting substance. Nature 345:167–170. DOI: https://doi.org/10.1038/345167a0, PMID: 2336108

Behringer RR, Finegold MJ, Cate RL. 1994. Müllerenhibiting substance function during mammalian sexual development. Cell 79:415–425. DOI: https://doi.org/10.1016/0092-8674(94)90251-8, PMID: 7954809

Bhasin M, Yuan L, Keskin DB, Ottu HH, Libermann TA, Oettgen P. 2010. Bioinformatic identification and characterization of human endothelial cell-restricted genes. BMC Genomics 11:342. DOI: https://doi.org/10.1186/1471-2164-11-342, PMID: 20509943

Branham WS, Sheehan DM, Zehr DR, Ridlon E, Nelson CJ. 1985. The postnatal ontogeny of rat uterine glands and age-related effects of 17 beta-estradiol. Endocrinology 117:2229–2237. DOI: https://doi.org/10.1210/en-do-117-5-2229, PMID: 4042984

Brody JR, Cunha GR. 1989. Histologic, Morphometric, and immunocytochemical analysis of myometrial development in rats and mice: I. normal development. American Journal of Anatomy 186:1–20. DOI: https://doi.org/10.1002/aja.1001860102, PMID: 2728286

Butler A, Hoffman F, Smibert P, Papalexi E, Satija R. 2018. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature Biotechnology 36:411–420. DOI: https://doi.org/10.1038/nbt.4096, PMID: 29608179

Chang K, Pastan I. 1996. Molecular cloning of Mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. PNAS 93:136–140. DOI: https://doi.org/10.1073/pnas.93.1.136, PMID: 8552591

Chen MJ, Karavitii LP, Macias CG, Roth DR, Gunn S, Sutton VR, Schlimmer B. 2014. State of the art review in hypospadias: challenges in diagnosis and medical management. Pediatric Endocrinology Reviews : PER 12:46–54. PMID: 25345085

Chiang S, Oliva E. 2013. Recent developments in uterine mesenchymal neoplasms. Histopathology 62:124–137. DOI: https://doi.org/10.1111/his.12048, PMID: 23240674

Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK. 2001. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Molecular Endocrinology 15:946–959. DOI: https://doi.org/10.1210/mend.15.6.0664, PMID: 11376113

Daikoku T, Cha J, Sun X, Tranguch S, Xie H, Fujita T, Hirota Y, Lydon J, DeMayo F, Maxson R, Dey SK. 2011. Conditional deletion of mhx homeobox genes in the uterus inhibits blastocyst implantation by altering uterine receptivity. Developmental Cell 21:1014–1025. DOI: https://doi.org/10.1016/j.devcel.2011.09.010, PMID: 22100262

Filant J, DeMayo FJ, Pru JK, Lydon JP, Spencer TE. 2014. Fibroblast growth factor receptor two (FGFR2) regulates uterine epithelial integrity and fertility in mice. Biology of Reproduction 90:7. DOI: https://doi.org/10.1095/biolreprod.113.114446, PMID: 24227756

Fujino A, Arango NA, Zhan Y, Manganaro TF, Li X, MacLaughlin DT, Donahoe PK. 2009. Cell migration and activated PI3K/AKT-directed elongation in the developing rat müllerian duct. Developmental Biology 325:351–362. DOI: https://doi.org/10.1016/j.ydbio.2008.10.027, PMID: 19013450

Hay BA, Li J, Guo M. 2018. Vectored gene delivery for lifetime animal contraception: overview and hurdles to implementation. Theriogenology 112:63–74. DOI: https://doi.org/10.1016/j.theriogenology.2017.11.003, PMID: 29169734

Hayashi K, Yoshiba K, Reardon SN, Rucker EB, Spencer TE, DeMayo FJ, Lydon JP, MacLean JA. 2011. WNTs in the neonatal mouse uterus: potential regulation of endometrial gland development. Biology of Reproduction 84:308–319. DOI: https://doi.org/10.1095/biolreprod.110.088818, PMID: 20962251

Herbst AL, Hubby MM, Blough RR, Azizi F. 1980. A comparison of pregnancy experience in DES-Exposed and DES-Unexposed daughters. Obstetrical & Gynecological Survey 35:473–477. DOI: https://doi.org/10.1097/00006254-198007000-00023

Hirakawa S, Hong YK, Harvey N, Schacht V, Matsuda K, Libermann T, Detmar M. 2003. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. The American Journal of Pathology 162:575–586. DOI: https://doi.org/10.1016/S0002-9440(10)63851-5, PMID: 12547715

Hrvatin S, Hochbaum DR, Nagy MA, Cicconet M, Robertson K, Cheadle L, Zilions R, Ratner A, Borges-Monroy R, Klein AM, Sabatini BL, Greenberg ME. 2018. Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex. Nature Neuroscience 21:120–129. DOI: https://doi.org/10.1038/s41593-017-0029-5, PMID: 29230054

Hsu JY, James KE, Bormann CL, Donahoe PK, Pépin D, Sabatini ME. 2018. Müllerian-Inhibiting substance/Anti-Müllerian hormone as a predictor of preterm birth in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 103:418–419. DOI: https://doi.org/10.1210/jc.2018-01320, PMID: 30239805

Imbeaud S, Carré-Eusébe D, Rey R, Belville C, Josso N, Picard JY. 1994. Molecular genetics of the persistent müllerian duct syndrome: a study of 19 families. Human Molecular Genetics 3:125–131. DOI: https://doi.org/10.1093/hmg/3.1.125, PMID: 8162013
Jamań SP, Arango NA, Mishyna Y, Hanks MC, Behringer RR. 2002. Requirement of Bmpr1a for müllerian duct regression during male sexual development. Nature Genetics 32:408–410. DOI: https://doi.org/10.1038/ng0302

Josse N, Picard JY, Traı̂ d D. 1976. The antimüllerian hormone. Recent Progress in Hormone Research 33:117–167. PMID: 801190

Jost A. 1947. Sur les effets de la castration précoce de l’embryon male de lapin. Comptes Rendus Des Séances De La Société De Biologie Et De Ses Filiales 141:125–129.

Kaneko K, Fujiyama K, Fujiiwara T, Kobayashi R, Ishida H, Harigae H, Shibahara S. 2014. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia. Haematologica 99:252–261. DOI: https://doi.org/10.3324/haematol.2013.085449

Kano M, Sosulski AE, Zhang L, Saatcioglu HD, Wang D, Nagykery N, Sabatini ME, Gao G, Donahoe PK, Pépin D. 2017. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. PNAS 114:E1688–E1697. DOI: https://doi.org/10.1073/pnas.1620729114

Klein AM, Mazutis L, Akartuna I, Tallapragada N, Veres A, Li V, Peshkin L, Weitz DA, Kirschner MW. 2015. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161:1187–1201. DOI: https://doi.org/10.1016/j.cell.2015.04.044

Kobayashi A, Stewart CA, Wang Y, Fujioka K, Thomas NC, Jamań SP, Behringer RR. 2011. β-Catenin is essential for müllerian duct regression during male sexual differentiation. Development 138:1967–1975. DOI: https://doi.org/10.1242/dev.056143

Kodama A, Yoshino O, Osuga Y, Harada M, Hasegawa A, Hamasaki K, Takamura M, Koga K, Hirota Y, Hirata T, Takemura Y, Yanoy T, Taketani Y. 2010. Progesterone decreases bone morphogenetic protein (BMP) expression and BMP7 inhibits decidualization and proliferation in endometrial stromal cells. Human Reproduction 25:751–756. DOI: https://doi.org/10.1093/humrep/dep455

Kurí-Hänninen T, Kallio S, Seuri R, Tyrväinen E, Liakka A, Tapanainen J, Sankilampi U, Dunkel L. 2011. Postnatal developmental changes in the pituitary-ovarian axis in preterm and term infant girls. The Journal of Clinical Endocrinology & Metabolism 96:3432–3439. DOI: https://doi.org/10.1210/jc.2011-1502

Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, Fleuren GJ, Warnaar SO. 1997. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. The Journal of Cell Biology 139:1337–1348. DOI: https://doi.org/10.1083/jcb.139.5.1337

MacDonald KP, Palmer JS, Cruon S, Seppanen E, Olver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B, Branstetter D, Smith J, Paxton RJ, Cerretti DP, Bonham L, Hill GR, Hume DA. 2010. An antibody against the colony-stimulating-factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116:3955–3963. DOI: https://doi.org/10.1182/blood-2010-02-266296

Medlock KL, Sheehan DM, Nelson CJ, Branham WS. 1988. Effects of postnatal DES treatment on uterine growth, development, and estrogen receptor levels. Journal of Steroid Biochemistry 29:527–532. DOI: https://doi.org/10.1016/0022-4731(88)90188-4

Miller C, Sassoon DA. 1998. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125:3201–3211. PMID: 9671592

Mishyna Y, Rey R, Finegold MJ, Matuzk MM, Josso N, Cate RL, Behringer RR. 1996. Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes & Development 10:2577–2587. DOI: https://doi.org/10.1101/gad.10.20.2577

Mishyna Y, Whitworth DJ, Racine C, Behringer RR. 1999. High specificity of Müllerian-inhibiting substance signaling in vivo. Endocrinology 140:2084–2088. DOI: https://doi.org/10.1210/endo.140.5.6705

Monsivais D, Clementi C, Peng J, Fullerton PT, Prunskaité-Hyyryläinen R, Vainio SJ, Matuzk MM. 2017. BMP7 induces uterine receptivity and blastocyst attachment. Endocrinology 158:979–992. DOI: https://doi.org/10.1210/en.2016-1629

Mucenski ML, Mahoney R, Adam M, Potter AS, Potter SS. 2019. Single cell RNA-seq study of wild type and Hox9,10,11 mutant developing uterus. Scientific Reports 9:4555. DOI: https://doi.org/10.1038/s41598-019-40923-w

Mullen RD, Wang Y, Liu B, Moore EL, Behringer RR. 2018. Osterix functions downstream of anti-Müllerian hormone signaling to regulate müllerian duct regression. PNAS 115:8382–8387. DOI: https://doi.org/10.1073/pnas.1721793115

Mullen RD, Behringer RR. 2014. Molecular genetics of müllerian duct formation, regression and differentiation. Sexual Development 8:281–296. DOI: https://doi.org/10.1159/000364935

Nik-Zainal S, Strick R, Storer M, Huang N, Rad R, Willatt L, Fitzgerald T, Martin V, Sandford R, Carter NP, Janecke AR, Renner SP, Oppelt PG, Oppelt P, Schulze C, Brucker S, Hurles M, Beckmann MW, Strissel PL, Shaw-Smith C. 2011. High incidence of recurrent copy number variants in patients with isolated and syndromic müllerian aplasia. Journal of Medical Genetics 48:197–204. DOI: https://doi.org/10.1136/jmg.2010.082412

Nonaka D, Chiriboga L, Rubin BP. 2008. Sox10: a pan-schwannian and melanocytic marker. The American Journal of Surgical Pathology 32:1291–1298. DOI: https://doi.org/10.1097/PAS.0b013e3181658c14

Patnaik SS, Brazile B, Dandolu V, Ryan PL, Liao J. 2015. Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a historical perspective. Gene 555:33–40. DOI: https://doi.org/10.1016/j.gene.2014.09.045

Saatcioglu HD, Wang D, Nagykery N, Sabatini ME, Gao G, Donahoe PK, Pépin D. 2002. Requirement of Bmpr1a for müllerian duct regression during male sexual development. Nature Genetics 32:408–410. DOI: https://doi.org/10.1038/ng0302

Sivasubramaniam, Sassoon DA. 1998. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125:3201–3211. PMID: 9671592

Sivasubramaniam, Sassoon DA. 1998. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125:3201–3211. PMID: 9671592

Sivasubramaniam, Sassoon DA. 1998. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125:3201–3211. PMID: 9671592

Sivasubramaniam, Sassoon DA. 1998. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125:3201–3211. PMID: 9671592

Sivasubramaniam, Sassoon DA. 1998. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125:3201–3211. PMID: 9671592

Sivasubramaniam, Sassoon DA. 1998. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125:3201–3211. PMID: 9671592
Pépin D, Hoang M, Nicolau F, Hendren K, Benedict LA, Al-Moujahed A, Sosulski A, Marmalidou A, Vavvas D, Donahoe PK. 2013. An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal mullerian inhibiting substance. Technology 1:63–71. DOI: https://doi.org/10.1142/S2339547813500076

Pépin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, Coletti CM, Yu A, Castro CM, Birrer MJ, Gao G, Donahoe PK. 2015. AAV9 delivering a modified human mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. PNAS 112: E4418–E4427. DOI: https://doi.org/10.1073/pnas.1510604112

Phippard DJ, Weber-Hall SJ, Sharpe PT, Naylor MS, Jayatalake H, Maas R, Woo I, Roberts-Clark D, Francis-West PH, Liu YH, Maxson R, Hill RE, Dale TC. 1996. Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during foetal and postnatal mammary gland development. Development 122:2729–2737. DOI: 10.1242/dev.000029

Prunskaite-Hyyryläinen R, Skovorodkin I, Xu Q, Minialainen I, Shan J, Vainio SJ. 2016. Wnt4 coordinates directional cell migration and extension of the Müllerian duct essential for ontogenesis of the female reproductive tract. Human Molecular Genetics 25:1059–1073. DOI: https://doi.org/10.1093/hmg/ddv621

Stros M, Polanská E, Struncová S, Pospíšilová S. 2009. HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase Ialpha. Nucleic Acids Research 37:2070–2086. DOI: https://doi.org/10.1093/nar/gkp067

Van Batavia JP, Kolon TF. 2016. Fertility in disorders of sex development: a review. Journal of Pediatric Urology 12:418–425. DOI: https://doi.org/10.1016/j.jpurol.2016.09.015

Van Esch H, Groenen P, Nesbit MA, Schuffenhauer S, Lichtner P, Vanderlinden I, Hill RE, Dale TC. 1996. Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during foetal and postnatal mammary gland development. Development 122:2729–2737. DOI: 10.1242/dev.000029

Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y. 2012. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. The Journal of Molecular Diagnostics : JMD 14:22–29. DOI: https://doi.org/10.1016/j.jmoldx.2011.08.002

Yin Y, Lin C, Zhang I, Fisher AV, Dhandha M, Ma L. 2015. Homeodomain transcription factor Msx-2 regulates uterine progenitor cell response to diethylstilbestrol. Journal of Stem Cell and Transplantation Biology 1:105. DOI: https://doi.org/10.19104/jstb.2015.105

Yin M, Zhou HJ, Lin C, Long L, Yang X, Zhang H, Taylor H, Min W. 2019. CD34+KLF4+ stromal stem cells contribute to endometrial regeneration and repair. Cell Reports 27:2709–2724. DOI: https://doi.org/10.1016/j.celrep.2019.04.088

Zeisel A, Hochgerner H, Lönnerberg P, Johnsson A, Memic F, van der Zwan J, Häring M, Braun E, Born L, LaManno G, Codeluppi S, Furlan A, Lee K, Skene N, Harris KD, Hjerling-Leffler J, Arenas E, Emfors P, Marklund U, Linnarsson S. 2018. Molecular architecture of the mouse nervous system. Cell 174:999–1014. DOI: https://doi.org/10.1016/j.cell.2018.06.021

Zilioni R, Engblom C, Pfrischarke C, Savova V, Zemmour D, Saatcioglu HD, Krishnan I, Maroni G, Meyerovitz CV, Kerwin CM, Choi S, Richards WG, De Rienzo A, Tenen DG, Bueno R, Levantini E, Pittet MJ, Klein AM. 2019. Single-Cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50:1317–1334. DOI: https://doi.org/10.1016/j.immuni.2019.03.009